参麦注射液联合比索洛尔治疗慢性肺源性心脏病急性发作期临床研究  

Clinical Study on Shenmai Injection Combined with Bisoprolol for Acute Exacerbation of Chronic Pulmonary Heart Disease

作　　者：沈秋跃 肖文玉 严祖喜[1] SHEN Qiuyue;XIAO Wenyu;YAN Zuxi

机构地区：[1]海盐县人民医院呼吸与危重症学科,浙江海盐314300 [2]平湖市中医院心血管内科,浙江平湖314200

出　　处：《新中医》2022年第16期57-60,共4页New Chinese Medicine

摘　　要：目的:观察参麦注射液联合比索洛尔治疗慢性肺源性心脏病(CPHD)急性发作期的临床疗效。方法:选取76例CPHD急性发作期患者,以随机数字表法分为对照组和观察组各38例。对照组给予比索洛尔治疗,观察组在对照组基础上给予参麦注射液治疗,2组均治疗14 d。比较2组临床疗效、并发症发生率;比较2组治疗前后肺功能、心功能分级、炎症因子及氨基末端脑钠尿肽(NT-proBNP)水平。结果:观察组总有效率86.84%,高于对照组63.16%(P<0.05)。治疗后,2组肺脉动压(PAP)均较治疗前降低(P<0.05),第1秒用力呼气容积(FEV1)、最大肺活量(FVC)均较治疗前升高(P<0.05);观察组PAP低于对照组(P<0.05),FEV1、FVC均高于对照组(P<0.05)。治疗后,2组纽约心脏病协会(NYHA)心功能分级均较治疗前改善(P<0.05),观察组NYHA心功能分级优于对照组(P<0.05)。治疗后,2组血清NT-proBNP、肿瘤坏死因子-α (TNF-α)、白细胞介素-6 (IL-6)水平均较治疗前降低(P<0.05),观察组血清NT-proBNP、TNF-α、IL-6水平均低于对照组(P<0.05)。观察组并发症发生率15.78%,低于对照组39.47%(P<0.05)。结论:参麦注射液联合比索洛尔治疗CPHD急性发作期疗效显著,可有效降低PAP和NT-proBNP水平,改善心肺功能,抑制炎症反应,减少并发症发生。Objective:To observe the clinical effect of the therapy of Shenmai injection combined with bisoprolol on acute exacerbation of chronic pulmonary heart disease(CPHD).Methods:A total of 76 patients with acute exacerbation of CPHD were selected and divided into the control group and the observation group according to the random number table method,with 38 cases in each group.The control group was treated with bisoprolol,and the observation group was additionally treated with Shenmai injection based on the treatment of the control group.Both groups were treated for 14 days.The clinical effects and incidence of complications were compared between the two groups;before and after treatment,the classification of the lung function and heart function and levels of inflammatory factors and N-terminal pro-brain natriuretic peptide(NT-proBNP) were compared between the two groups.Results:The total effective rate was86.84% in the observation group,higher than that of 63.16% in the control group(P<0.05).After treatment,the levels of pulmonary artery pressure(PAP) in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of forced expiratory volume in one second(FEV1) and forced vital capacity(FVC) were increased(P<0.05);the level of PAP in the observation group was lower than that in the control group(P<0.05),and the levels of FEV1and FVC in the observation group were higher(P<0.05).After treatment,the grading of heart function according to New York Heart Association(NYHA) in the two groups was improved when respectively compared with that before treatment(P<0.05),and the grading in the observation group was better than that in the control group(P<0.05).After treatment,the levels of serum NT-proBNP,tumor necrosis factor-α(TNF-α) and interleukin-6(IL-6) in the two groups were decreased when compared with those before treatment(P<0.05),and the above three levels in the observation group were lower than those in the control group(P<0.05).The incidence of complications was 15.78% in the obse

关 键 词：慢性肺源性心脏病 参麦注射液 比索洛尔 心功能 肺功能 炎症因子 氨基末端脑钠尿肽 并发症 

分 类 号：R541.5[医药卫生—心血管疾病]